| Methods for treating blood disorders -> Monitor Keywords |
|
|
 
Methods for treating blood disordersRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Lymphokine, InterleukinMethods for treating blood disorders description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20080075692, Methods for treating blood disorders. Brief Patent Description - Full Patent Description - Patent Application Claims
CROSS-REFERENCE TO RELATED APPLICATION [0001] This application claims the benefit under 35 U.S.C. .sctn. 119(e) of U.S. Provisional Patent Application No. 60/799,054 filed May 9, 2006, which provisional application is incorporated herein by reference in its entirety. BACKGROUND [0002] 1. Field of the Invention [0003] The present invention relates to methods and compounds for the treatment of blood disorders. [0004] 2. Description of the Related Art [0005] The major function of red blood cells is to transport oxygen to tissues of the body, while minor functions include the transportation of nutrients and cytokines and the absorption of cellular metabolites. Anemia, defined as a loss of red blood cells or red blood cell capacity resulting in the reduction in the ability of the blood to transport oxygen, may be chronic or acute. Chronic anemia may be caused by extrinsic red blood cell abnormalities, intrinsic abnormalities or impaired production of red blood cells. Extrinsic or extra-corpuscular abnormalities include antibody-mediated disorders such as transfusion reactions and erythroblastosis, mechanical trauma to red cells such as micro-angiopathic hemolytic anemias, thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. In addition, infections by parasites such as Plasmodium, chemical injuries from, for example, lead poisoning, and sequestration in the mononuclear system such as by hyperspienism can result in red blood cell disorders and deficiencies. [0006] Impaired red blood cell production can occur by disturbing the proliferation and differentiation of the stem cells or committed cells. Some of the more common diseases of red cell production include aplastic anemia, sickle cell anemia, .beta.-thalassemia, hypoplastic anemia, pure red cell aplasia and anemia associated with renal failure or endocrine disorders. Disturbances of the proliferation and differentiation of erythroblasts include defects in DNA synthesis such as impaired utilization of vitamin B.sub.12 or folic acid and the megaloblastic anemias, defects in heme or globin synthesis, and anemias of unknown origins such as sideroblastic anemia, anemia associated with chronic infections such as malaria, trypanosomiasis, HIV, hepatitis virus or other viruses, and myelophthisic anemias caused by marrow deficiencies. [0007] Symptoms of anemia include feelings of weakness or fatigue, pallor, shortness of breath, an increase in cardiac output, which may lead to palpitations and sweatiness. In severe cases, anemia can lead to death by heart failure. Current treatments for anemia depend on the type of anemia the patient suffers from. Monitoring of the diet to increase iron intake may be prescribed, as well as iron supplementation. In some cases, medication or blood transfusions may be necessary. [0008] Sickle cell disease and .beta.-thalassemia are two of the most common genetic disorders in the word. These disorders are caused by molecular mutations affecting the .beta.-globin genes for adult hemoglobin A (.alpha.2.beta.2), and it has been established that these disorders can be ameliorated by reactivating production of fetal hemoglobin (HbF, .alpha.2.gamma.2) in the patients' blood. Even small increments in fetal hemoglobin decreases morbidity and mortality in sickle cell disease, while higher levels are necessary to completely ameliorate the symptoms. In .beta.-thalassemia, increases in fetal globin synthesis, which reduces the excess unbalanced .alpha.-globin chains by 10%, is often enough to decrease the anemia to a level which does not require regular blood transfusions. [0009] Short chain fatty acids and derivatives of 2-9 carbons induce expression of .gamma.-globin in cultured erythroid cells, animal models and reporter gene assays, which test activity in activating the .gamma.-globin gene promoter. Several short chain fatty acids induce the .gamma.-globin promoter and have biologic and clinical activity. Pharmacological re-introduction of HbF has been achieved in patients with a prototype short-chain fatty acid, arginine butyrate, resulting in sufficient levels of HbF to ameliorate anemia and reduce clinical complications. Patients treated in a Phase II trial with pulsed butyrate have experienced both biochemical and clinical improvement in their diseases, with excellent safety profiles. However, the prototype short chain fatty acids have limitations as therapeutics. Arginine butyrate and phenylbutyrate require 100 .mu.M levels in vitro and are rapidly metabolized in vivo, necessitating large quantities (20 g for sodium phenyl butyrate), an intravenous infusion for arginine butyrate and careful adjustment of dosing to prevent secondary suppression of erythopoiesis. [0010] While advances have been made in this field, there remains a need for new and/or improved methods for treating and preventing blood disorders generally as well as for compounds and pharmaceutical compositions for the same. BRIEF SUMMARY [0011] The present invention pertains, at least in part, to methods for treating or preventing a blood disorder in a subject by administering to the subject an effective amount of a compound of formula I: wherein [0012] R.sup.1 is hydroxy or alkoxy; [0013] X is C(O), C(S), SO, SO.sub.2 or PO.sub.2; [0014] R.sup.2 and R.sup.3 are each independently hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, alkoxy, amino, alkylamino or heterocyclic; [0015] R.sup.4 is alkyl, cycloalkyl, alkenyl, alkynyl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, heteroaryl, halogen or [0016] R.sup.5 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R.sup.6 to form a ring; [0017] R.sup.6 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R.sup.5 or R.sup.7 to form a ring; [0018] R.sup.7 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R.sup.6 or R.sup.8 to form a ring; [0019] R.sup.8 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R.sup.7 or R.sup.9 to form a ring; [0020] R.sup.9 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, nitro, halogen or optionally linked to R.sup.8 to form a ring; [0021] and racemates, isolated enantiomers or diastereomers, and pharmaceutically acceptable salts thereof; Continue reading about Methods for treating blood disorders... Full patent description for Methods for treating blood disorders Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Methods for treating blood disorders patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Methods for treating blood disorders or other areas of interest. ### Previous Patent Application: Aqueous preparations comprising at least one water-soluble or water-dispersible copolymer with cationgenic groups Next Patent Application: Methods for treating viral infection using il-28 and il-29 cysteine mutants Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Methods for treating blood disorders patent info. IP-related news and info Results in 0.64373 seconds Other interesting Feshpatents.com categories: Tyco , Unilever , Warner-lambert , 3m 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
